Zacks - EYEGATE PHARMACEUTICALS INC (EYEG) EYEG: Compelling OBG Data in PE and PRK. Could Set Up Regulatory Filings

Report

Zacks

EYEG: Compelling OBG Data in PE and PRK. Could Set Up Regulatory Filings

30/11/2018 24 EN

Underlying

EYEGATE PHARMACEUTICALS INC

See profile

US30233M1071 United States

Provider

Zacks

Zacks Investment Research is a Chicago based firm with over 30 years of experience in providing institutional and individual investors with the analytical tools and financial information necessary to the success of their investment process.

See profile

Other Reports on these Companies

Zacks

EYEG: Building towards FDA filings

May 19, 2020 May 19, 2020 8 EN

Zacks

EYEG: OBG-PRK Pivotal Data Upcoming, 2020 Launch Feasible. OBG-PE Pre-Pivotal Study Moving Quick, Pivotal in 2020?

November 14, 2019 November 14, 2019 18 EN

Edison Investment Research

EyeGate Pharmaceuticals - OBG pivotal study recruitment on schedule

EyeGateâ€™s Ocular Bandage Gel (OBG) is progressing in its ongoing pivotal study in corneal wound healing following photorefractive keratectomy (PRK) surgery. The firm recently met its 75% recruitment target (planned n=260 patients) and data are expected by YE19. If positive, it should lead to a market approval filing in H120. EyeGate will shortly begin a follow-on pilot study in punctate epitheliopathies (PE), a much larger indication that is related to dry eye disease (DED). Prior OBG PRK studies showed improved wound healing and a prior PE pilot trial showed improvement in patient symptoms,...

October 7, 2019 October 7, 2019 2 EN

PBSV: Steady as she goes

July 24, 2020 July 24, 2020 5 EN

BCLI: KOL Event Gives Overview of the use of NurOwnÂ® in Alzheimerâ€™s Disease; Raising Valuation to $25/Share...

July 9, 2020 July 9, 2020 7 EN

MNOV: FDA Gives OK to Initiate Clinical Trial of MN-166 to Prevent ARDS in COVID- 19 Patients...

July 2, 2020 July 2, 2020 7 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

EYEG: Compelling OBG Data in PE and PRK. Could Set Up Regulatory Filings

EYEG: Building towards FDA filings

EYEG: OBG-PRK Pivotal Data Upcoming, 2020 Launch Feasible. OBG-PE Pre-Pivotal Study Moving Quick, Pivotal in 2020?

EyeGate Pharmaceuticals - OBG pivotal study recruitment on schedule

PBSV: Steady as she goes

BCLI: KOL Event Gives Overview of the use of NurOwnÂ® in Alzheimerâ€™s Disease; Raising Valuation to $25/Share...

MNOV: FDA Gives OK to Initiate Clinical Trial of MN-166 to Prevent ARDS in COVID- 19 Patients...

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe